Ravi K Amaravadi
Overview
Explore the profile of Ravi K Amaravadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
15784
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crissey M, Versace A, Bhardwaj M, Jain V, Liu S, Singh A, et al.
Autophagy
. 2024 Sep;
21(2):394-406.
PMID: 39265628
Macroautophagy/autophagy-lysosome function promotes growth and survival of cancer cells, making them attractive targets for cancer therapy. One intriguing lysosomal target is PPT1 (palmitoyl-protein thioesterase 1). PPT1 inhibitors derived from chloroquine...
2.
Ma K, Mitchell T, Dougher M, Sharon C, Tortorello G, Elder D, et al.
Clin Cancer Res
. 2024 Sep;
30(21):4987-4994.
PMID: 39248505
Purpose: Neoadjuvant anti-PD-1 therapy in melanoma may increase tumor-infiltrating lymphocytes (TIL), and more TIL are associated with better treatment response. A major pathologic response (MPR) in melanoma after neoadjuvant anti-PD-1...
3.
Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, et al.
Cancer Cell
. 2024 Aug;
42(9):1582-1597.e10.
PMID: 39214097
Combination checkpoint blockade with anti-PD-1 and anti-CTLA-4 antibodies has shown promising efficacy in melanoma. However, the underlying mechanism in humans remains unclear. Here, we perform paired single-cell RNA and T ...
4.
Axfors C, Schmitt A, Janiaud P, Vant Hooft J, Abd-Elsalam S, Abdo E, et al.
Nat Commun
. 2024 Feb;
15(1):1075.
PMID: 38316844
No abstract available.
5.
Anderson T, Chang B, Huang A, Xu X, Yoon D, Shang C, et al.
Clin Cancer Res
. 2024 Jan;
30(9):1758-1767.
PMID: 38263597
Purpose: Immunologic response to anti-programmed cell death protein 1 (PD-1) therapy can occur rapidly with T-cell responses detectable in as little as one week. Given that activated immune cells are...
6.
Shah P, Huang A, Xu X, Orlowski R, Amaravadi R, Schuchter L, et al.
Cancer Res Commun
. 2023 Jun;
3(5):821-829.
PMID: 37377890
Purpose: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor...
7.
Jain V, Singh M, Amaravadi R
Trends Pharmacol Sci
. 2023 Mar;
44(5):290-302.
PMID: 36931971
Autophagy is a cellular homeostasis mechanism that fuels the proliferation and survival of advanced cancers by degrading and recycling organelles and proteins. Preclinical studies have identified that within an established...
8.
Bhardwaj M, Lee J, Versace A, Harper S, Goldman A, Crissey M, et al.
J Clin Invest
. 2023 Feb;
133(8).
PMID: 36795483
Lysosomal inhibition elicited by palmitoyl-protein thioesterase 1 (PPT1) inhibitors such as DC661 can produce cell death, but the mechanism for this is not completely understood. Programmed cell death pathways (autophagy,...
9.
Jain V, Harper S, Versace A, Fingerman D, Brown G, Bhardwaj M, et al.
Cancer Discov
. 2022 Nov;
13(2):454-473.
PMID: 36331284
Significance: We discovered UGCG-dependent lipid remodeling drives resistance to LAI. Targeting UGCG with a drug approved for a lysosomal storage disorder enhanced LAI antitumor activity without toxicity. LAI and UGCG...
10.
Sharma G, Ojha R, Noguera-Ortega E, Rebecca V, Attanasio J, Liu S, et al.
JCI Insight
. 2022 Oct;
7(20).
PMID: 36278493
No abstract available.